Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Erasca In-licenses Two China RAS Candidates in Two Deals Worth $349 Million

publication date: May 17, 2024

San Diego’s Erasca acquired rights for two China-developed pre-clinical RAS candidates in two separate agreements, while it is sidelining two of its own candidates and temporarily discontinuing development on a third candidate. Erasca will also raise $160 million from investors. The company acquired ex-China rights to a pan-RAS molecular glue (ERAS-0015) from Joyo Pharmatech of Guangzhou in a $189 million deal and global rights to a pan-KRAS inhibitor (ERAS-4001) from Sichuan Medshine Discovery in a $170 million agreement. More details....

Stock Symbol: (NSDQ: ERAS)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital